Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900422 | 1.00 | TACR1 (0.43) | TACR1KCNH2CCR2ESRRGMCHR1 | |
| SCHEMBL19443100 | 1.00 | TACR1 (0.43) | TACR1KCNH2CCR2ESRRGMCHR1 | |
| SCHEMBL18244997 | 0.91 | TACR1 (0.44) | TACR1KCNH2CCR2ESRRGKDM4E | |
| SCHEMBL21900586 | 0.88 | ESRRG (0.38) | TACR1KCNH2CCR2ESRRG | |
| SCHEMBL20013955 | 0.86 | LMNA (0.38) | KCNH2CCR2KDM4ECHRM4CHRM1 | |
| SCHEMBL24433921 | 0.86 | TLR9 (0.35) | TACR1KCNH2CCR2CHRM4CHRM1 | |
| SCHEMBL20013833 | 0.85 | TACR1 (0.34) | TACR1KCNH2CCR2CHRM4CHRM1 | |
| SCHEMBL19443128 | 0.84 | TACR1 (0.35) | TACR1KCNH2CCR2KDM4EMEN1 | |
| SCHEMBL20013739 | 0.83 | KCNH2 (0.35) | TACR1KCNH2CCR2CHRM4CHRM1 | |
| SCHEMBL21900732 | 0.82 | HRH3 (0.35) | TACR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | TACR1 201/4885KCNH2 4506/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.